This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.
Switching from one vaccine product to another can have a significant impact on a country’s budget. For Palestine’s rotavirus vaccination program, a switch paid off.
This brief describes an economic analysis conducted by PATH in partnership with the Rostropovich-Vishnevskaya Foundation and the Palestinian Ministry of Health to assess the economic implications of Palestine's switch from ROTARIX to ROTAVAC.
Publication date: December 2020